Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

New York, Jan 18, 2026, 05:48 EST — Market closed

• Kenvue shares ended Friday at $17.20, slipping 0.35%.
• Proxy adviser ISS has called on investors to support Kimberly-Clark’s upcoming acquisition of Kenvue, with a vote scheduled for Jan. 29.
• Kenvue submitted additional merger disclosures following lawsuits tied to the deal, broadening concerns over closing risks and timing.

Kenvue (KVUE) shares slipped 0.35% to close at $17.20 on Friday, as investors digested a crucial nod for its planned sale to Kimberly-Clark. Proxy adviser Institutional Shareholder Services gave the green light, saying “on balance, support for the transaction is warranted.” Still, ISS flagged ongoing market jitters and legal risks as key concerns for shareholders. With proxy advisers often influencing big institutional votes, both companies’ investors are set to weigh in on Jan. 29. Reuters

The timing is tight and inconvenient. U.S. stock markets are closed for the weekend and will remain shut Monday in observance of Martin Luther King Jr. Day, squeezing the window for traders to adjust positions before regular trading kicks back in on Tuesday.

Kenvue took action on the legal front as well. In a Form 8-K filed Jan. 16, the company said it voluntarily updated its joint proxy materials following shareholder lawsuits and demand letters complaining about missing disclosures and pushing to delay the vote. The board stood firm, reiterating its “FOR” recommendation on the merger proposals. Under the deal, Kenvue shareholders will get $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share. Based on Kimberly-Clark’s last price near $99.32, that values each Kenvue share at about $18.03 — a roughly 4.6% premium over Kenvue’s Friday close, known as the deal spread among merger traders.

Kimberly-Clark’s filing revealed some of the banker calculations behind the deal pitch. J.P. Morgan expects roughly $23.4 million in fees for arranging or providing financing. The filing also outlined parts of Centerview’s valuation, highlighting a peer group that included Haleon, Reckitt Benckiser, and Procter & Gamble. Centerview’s comparable-company analysis suggested an implied per-share range for Kenvue between $18.07 and $21.73, based on 2026 EBITDA — a key operating profit metric. Its discounted cash flow model, which values a company by forecasting and discounting future cash flows, applied discount rates from 6.75% to 8.50%.

Underlying the vote remains a market wary of the deal, with concerns swirling around product-liability risks and doubts over whether the touted benefits outweigh the complications. ISS acknowledged this skepticism instead of brushing it aside.

The structure is key for the stock on Tuesday. Since this is a cash-and-stock deal, Kenvue’s price moves not only on its own fundamentals but also in sync with Kimberly-Clark’s shares. If Kimberly-Clark’s stock falls, the value of the stock portion declines too, causing the “spread” to widen—even if the chances of closing remain steady.

There’s also a straightforward mechanical risk: votes might not go through. A sudden change in shareholder sentiment, stronger public pushback, or an unforeseen court ruling that drags out the timeline could delay the deal and send Kenvue back to trading on standalone prospects. Another, more subtle downside is that Kimberly-Clark’s stock could weaken ahead of the vote, dragging down the implied value even if shareholders eventually give the green light.

Another key event is just around the corner. Kimberly-Clark plans to release its fourth-quarter 2025 results on Jan. 27, just two days ahead of the shareholder meetings. The report’s numbers and tone could shake up Kimberly-Clark’s stock—and by extension, the implied offer price for Kenvue.

The focus now shifts to the Jan. 29 votes and any new filings or proxy-adviser updates that might emerge beforehand. Traders will monitor if the spread narrows toward the implied offer price or if the market continues to factor in delays and legal complications.

Kenvue holders face a straightforward schedule this week: markets reopen Tuesday after the holiday, Kimberly-Clark reports earnings on Jan. 27, and on Jan. 29, the crucial vote will determine if this spread trade holds or unravels.

Related articles: NYSE:KVUE

▶

18 August 2026

Kenvue Shares Drop 2.1% While Deal Calculations Account for 88% of Decline in Tylenol Maker

17 August 2026

Kenvue’s $1.1 Billion Beauty Segment Faces Scrutiny as Neutrogena Draws Viral Backlash

▶

24 June 2026

Kenvue shares rise as Kimberly-Clark deal spread holds near 2%

14 October 2025

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised